APA (7th ed.) Citation

C, T., S, J., K, T., EE, C., RJ, C., TB, O., . . . AM, D. (2026). SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. Vaccine, 75, 128290. https://doi.org/10.1016/j.vaccine.2026.128290

Chicago Style (17th ed.) Citation

C, Tøndel, et al. "SARS-CoV-2 T-cell Vaccine VB10.2210 Induces Broad T-cell Responses in a Phase 1/2 Open-label Clinical Trial." Vaccine 75 (2026): 128290. https://doi.org/10.1016/j.vaccine.2026.128290.

MLA (9th ed.) Citation

C, Tøndel, et al. "SARS-CoV-2 T-cell Vaccine VB10.2210 Induces Broad T-cell Responses in a Phase 1/2 Open-label Clinical Trial." Vaccine, vol. 75, 2026, p. 128290, https://doi.org/10.1016/j.vaccine.2026.128290.